USC launches transformational AI initiative with $200 million gift
On May 5, 2026, the University of Southern California (USC) announced a transformational initiative that will leverage AI…
-
-
UCB to acquire Candid Therapeutics for more Than $2 Bllion, building upon its existing immunology pipeline
On May 3, 2026, UCB, a global biopharmaceutical company, announced signing of a definitive agreement under which it…
-
Canada approves second generic semaglutide, the first G7 country to do so
On May 1, 2026, Health Canada authorized a second generic semaglutide injection. Health Canada is currently reviewing seven other…
-
Artificial Intelligence | Biotechnology | Diagnostics | Disease | Genomics | Neurology | Non-Profit Research | Oncology | Therapeutics
Biohub Launches the Virtual Biology Initiative to Galvanize a Global Effort to Create the Open Data Foundation for AI-Accelerated Biolog
On Apr. 29, 2026, Biohub announced the Virtual Biology Initiative, a landmark five-year initiative to galvanize a global…
-
UK Trials Show Paxlovid speeds recovery, but doesn’t reduce hospitalization in vaccinated patients
On Apr. 23, 2026. two national trials published in the New England Journal of Medicine report Paxlovid (nirmatrelvir-ritonavir)…
-
Biotechnology | Disease | FDA | Therapeutics
FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss
On Apr. 23, 2026, the U.S. Food and Drug Administration (FDA) approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual…
-
Lilly to acquire Kelonia Therapeutics for $3.25 billion to advance in vivo CAR-T cell therapies
On Apr. 20, 2026, Eli Lilly and Kelonia Therapeutics, a clinical-stage biotechnology company pioneering in vivo gene delivery,…
-
Kailera nets $625M, biotech’s biggest-ever IPO
On Apr. 17, 2026, Kailera Therapeutics, a high-profile drug startup aiming to compete with Novo Nordisk and Eli…
-
Biotechnology | Diagnostics | Disease | Genomics | Oncology | Therapeutics
Roche Expands Foundation Medicine With Acquisition of SAGA Diagnostics’ Tumor-Informed Molecular Residual Disease Platform for $595 million
On Apr. 15, 2026, Foundation Medicine, an independent affiliate of the Roche group, announced it is set to…
-
Amazon Bio Discovery Launches lab-in-the-loop drug discovery
On Apr. 14, 2026, Amazon announces launching AI BioDiscovery Contract Research Orgainzation. Lab-in-the-loop drug discovery has transformed research…
-
Novo Nordisk partners with OpenAI in weight loss drug race
On Apr. 14, 2026, Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, is partnering with OpenAI…
-
Biotechnology | Diagnostics | Genomics | Infectious Disease | Medicine | Nanotechnology | Neurology | NIH | Non-Profit Research | Oncology | Pharmaceutical | Rare Disease | Stem Cell | Therapeutics | U.S. Congress | Vaccine | Women's Health
Trump administration drops court fight to cap NIH payments for research overhead costs
On Apr. 8, 2026, the Trump administration will not be asking the Supreme Court to take up its…
-
Gilead to Acquire Tubulis for $5 Billion to Further Strengthen Oncology Pipeline
On Apr. 7, 2026, Gilead Sciences announced it has entered into a definitive agreement to acquire Tubulis, a…
-
Cornell Scientists take big step toward safe, reversible male contraception
On Apr. 7, 2026, Cornell scientists announce they have taken a major step toward developing a safe, reversible,…
-
Agriculture | Biotechnology | Diagnostics | Infectious Disease | Medical Device | Neurology | NIH | Non-Profit Research | Oncology | Pharmaceutical | Stem Cell | Therapeutics | U.S. Congress | Vaccine | Veterinary | Women's Health
Life Science Industry’s Rapid Growth in Washington State Challenged by NIH Budget Cuts
On Apr. 7, 2026, LifeScienceHistory.com, formerly WashingtonLifeScience.com, announces release of a report highlighting the challenges of Washington State’s…
-
FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
On Apr. 1, 2026, Eli Lilly announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for…
-
Artificial Intelligence | Biotechnology | Cloning | CRISPR | Diagnostics | Genomics | Implants | Infectious Disease | Life Science History | Medical Device | Nanotechnology | Neurology | NIH | Non-Profit Research | Pharmaceutical | Quantum | Therapeutics | U.S. Congress
China Tops U.S. in R&D Spending
On Mar. 31, 2026, the Organisation for Economic Co-operation and Development (OECD), reports that China has officially crept…
-
Biogen to Acquire Apellis for $5.6 billion, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease
On Mar. 31, 2026, Biogen and Apellis Pharmaceuticals announced the companies have entered into a definitive agreement under…
-
Biotechnology | Disease | FDA | Therapeutics
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
On Mar. 30, 2026, Biogen announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of…
-
Artificial Intelligence | Biotechnology | Diagnostics | Infectious Disease | Medical Device | Neurology | Pharmaceutical | Therapeutics
China biotech deals hit record as innovative drugs draw interest of multinationals
On Mar. 29, 2026, The South China Morning Post reported the cross-border outlicensing activities of Chinese biotech firms…
-
Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly
On Mar. 29, 2026, generative-AI drug developer Insilico Medicine announced that it has agreed to a global licensing…
-
Biotechnology | Clinical Research | Diagnostics | Environmental | Infectious Disease | NIH | Non-Profit Research | Rare Disease | Therapeutics | Vaccine
NIH restrictions on foreign research partnerships significantly impacted 1 in 4 U.S. scientists
On Mar. 27, 2026, a STAT survey conducted of nearly 1,000 National Institutes of Health (NIH) -supported scientists,…
-
Novartis to acquire Excellergy for $2 Billion, building on allergy leadership with next-generation anti-IgE innovation
On Mar. 27, 2026, Novartis announced an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE…
-
Implantable ‘Living Pharmacy’ Produces Multiple Drugs Inside the Body
On Mar. 27, 2026, A multi-institutional team of scientists, co-led by Northwestern University, has taken a crucial step…
-
New enzyme atlas rewrites decades of biology research
On Mar. 23, 2026, The Walter and Eliza Hall Institute of Medical Research (WEHI) researchers have led a…
-
Novartis to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline for $3 Billion
On Mar. 20, 2026, Novartis announced an agreement with Synnovation Therapeutics, to acquire SNV4818, a pan-mutant‑selective PI3Kα inhibitor,…
-
Biotechnology | Disease | FDA | Therapeutics
FDA approves new higher-dose version of Wegovy shots
On Mar. 19, 2026, The U.S. Food and Drug Administration approved a 7.2-milligram dose of Danish drugmaker Novo…
-
Agriculture | Artificial Intelligence | Biotechnology | Diagnostics | Environmental | FDA | Genomics | Imaging | Infectious Disease | Medical Device | Medicine | Nanotechnology | Neurology | NIH | Non-Profit Research | Oncology | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine | Veterinary | Women's Health
National survey of NIH-funded researchers shows precarious state of U.S. science — ‘This is like the Titanic’
On Mar. 19, 2026, a nationwide STAT survey of federally funded researchers reveals that, a year after Donald…
-
Biotechnology | Cardiology | Diagnostics | FDA | Neurology | NIH | Rare Disease | Therapeutics | Women's Health
NIH invests $150 million in human-based research to reduce use of animal models
On Mar. 18, 2026, the National Institutes of Health (NIH) announced more than $150 million to develop and…
-
New Genetic Risk Score Better Predicts Diabetes, Obesity and Downstream Complications
On Mar. 16, 2026, investigators from Mass General Brigham announce they have built metabolic polygenic risk scores (PRS) for predicting…
